Introduction
Use of multiagent chemotherapy alone or in combination with radiation therapy (XRT) cures more than 90% of adolescent patients with Hodgkin's lymphoma (HL). 1, 2 High-dose chemotherapy and autologous SCT (HDC ASCT) is well-accepted therapy for most adult patients with HL who have persistent re-relapsed disease. HDC ASCT has shown superior event-free survival (EFS) in this group when compared with salvage chemotherapy alone. 3, 4 Patients with refractory HL who receive conventional dose salvage chemotherapy have extremely poor outcome. 5, 6 HDC ASCT is a well-accepted approach for adult patients with primary refractory HL (PR-HL). [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] HDC ASCT is also a common practice in adolescent patients with relapsed or refractory HL but the literature is limited and often a pediatric population is included in the analysis. [21] [22] [23] [24] [25] [26] [27] 
Patients and methods
This was a retrospective cohort analysis approved by the Institutional Research Advisory Counsel. All patients or their parents provided informed consent for salvage chemotherapy, related procedures and HDC ASCT as per institutional requirements.
All patients with relapsed or PR-HL who had HDC ASCT were identified from Oncology Data Unit. From 1996 to May 2007, 135 consecutive patients with biopsy-proven HL underwent HDC ASCT. Of these, 58 patients were between the ages of 14 and 21 at the time of ASCT. All the patients' paper and electronic charts were reviewed retrospectively to collect required data. Before HDC ASCT, all patients were required to have adequate hematological, renal, hepatic, pulmonary and cardiac functions.
All patients were staged according to Ann Arbor staging system. Bulky disease was defined as mediastinal mass greater than or equal to one-third of the maximum thoracic wall diameter or any mass equal to or greater than 8 cm. We used WHO response criteria: complete remission (CR), disappearance of all lymphoma-related abnormalities; partial remission (PR), more than 50% reduction; no response or stable disease (NR/SD) as less than PR; progressive disease (PD) as appearance of any new lesion or more than 25% increase in any of the previous lesion or appearance of disease-related symptoms. PR-HL is defined as PR, NR/SD or PD after planned multiagent chemotherapy with or without XRT or relapsing within 3 months of finishing the planned treatment after achieving a CR or CR unconfirmed (CRu), commonly referred as short-lived CR. Patients had restaging radiological evaluation after HDC ASCT preferably around day 100 to assess the disease status and as clinically indicated thereafter.
Except Patients on primary chemotherapy (ABVD (driamycin, bleomycin, vinblastine, dacarbazine), COPP/ABVD, others) had response evaluation (both clinical and radiological) in the middle and at the end of planned initial treatment. After starting salvage chemotherapy, all patients had response evaluation after 2-3 cycles of salvage chemotherapy.
Statistical analysis
Data were collected both at the time of diagnosis and before the initiation of salvage chemotherapy (after relapse or induction failure). Factors reported in the International Prognostic Factors Project are also included. 29 Response to salvage chemotherapy was also evaluated separately and reported.
SPSS Version 12 was used for statistical analyses. Survival analyses were performed using Kaplan-Meier method and compared using the log-rank test. OS was calculated both from the diagnosis and from the date of ASCT. Event is defined as presence of disease after HDC ASCT, death due to any cause or relapse after HDC ASCT. EFS is calculated from the date of stem cell infusion. The impact of the following prognostic factors (at the time of relapse or progression before the start of salvage chemotherapy) was evaluated using one-way analyses of variance (ANOVA) and multivariate regression analysis for OS and EFS as dependent variable: B symptoms, previous XRT, relapsed vs refractory disease, bulky disease, mediastinal, spleen and extranodal involvement, HL IPI, good (0, 1, 2) vs bad (X3), elevated lactate dehydrogenase (LDH) and response to salvage chemotherapy. Results were considered significant if Pp0.05 (two sided). Response to salvage chemotherapy was separately analyzed as an additional factor (CR/CRu vs PR/NR/SD and also as CR/CRu/PR vs NR/SD among all the factors mentioned above and reported separately. Tables 1 and 2.  Table 2 also provides details of various prognostic factors at diagnosis and before the salvage chemotherapy.
Results

Patient characteristics are shown in
Thirty-nine patients (67%) had biopsy-proven reconfirmation of disease at the time of relapse/progression. Of all patients, 19 of 24 (79%) patients with relapsed disease vs 20 of 34 (59%) PR-HL patients had tissue reconfirmation (P ¼ 0.089). Other patients had unequivocal evidence of relapse or PR-HL based on clinical and radiological evaluation.
ESHAP was the primary salvage chemotherapy used in our institution. Fifty-one (88%) of these patients had ESHAP as a second line chemotherapy (first line salvage). Six patients had ESHAP as second line salvage. Three of these patients had this at second relapse as salvage. These patients had CR duration of 3-5 years; at first relapse, they received COPP/ABV, COPP and APPE (Ara-c, platinum, prednisone, etoposide) chemotherapy as salvage in the pediatrics section. Two other patients had resistant relapse and received COPP/ABVD for relapse with PR, one received ESHAP and other one APPE chemo in the pediatrics section. Last patient had ABVD and then COPP, both with no response and received ESHAP after that. Patients with progressive disease were not eligible for HDC Table 3 . Before HDC ASCT, 15 (26%) patients were in CR/CRu because of salvage chemotherapy, 36 (62%) had PR and 7 (12%) had NR or SD. Fifty-three (91%) patients had ESHAP þ G-CSF as mobilization regimen for PBSC. 28 Two (4%) patient had cytoxan and G-CSF for mobilization. One patient failed both ESHAP and then cytoxan and G-CSF mobilization, and required BM harvest. One patient had IMVP-16 (ifosfamide, methotrexate, etoposide) þ G-CSF and other had BM harvest þ cytoxan and G-CSF as mobilization regimen. Median CD34 þ cells/kg collected was 9.5 Â 10 6 /kg. Twenty-two patients had XRT before the initiation of salvage chemotherapy. Of these 22 patients, 11 had relapsed disease and 11 had PR-HL (5 PR and 6 early relapse within 3 months). Of these 22 patients, 14 had bulky disease and 17 had mediastinal involvement. Field of radiation was primarily covering the mediastinum as mantle/modified mantle/mediastinum in 16, type of modified mantle þ spleen±para-aortic lymph nodes in 3 and 3 patients had axilla (1), neck (1) or abdominal radiation (1). Dose of radiation was 1500-2600 cGy in 9 patients, 3000-3600 cGy in 10 and others (3460, 3940 cGy and unknown in outside institution) in 3 patients. In relation to the radiation field and persistent/progressive disease or relapse, it was only inside the radiation field in seven patients, only outside the radiation field in six and both inside and outside the field in nine patients.
Post-HDC ASCT evaluation results are shown in Table 3 . Forty-one (71%) patients were in CR (fifteen of these patients were already in CR/CRu after salvage chemotherapy). Seven (12%) achieved PR and one (2%) had NR/SD after salvage chemotherapy. Nine (15%) patients had PD before or at the time of first post transplant evaluation around day 100. No patient had treatment-related death. After HDC and ASCT, two patients with PR had mediastinal þ neck (4140 cGy) and modified mantle (3600 cGy) XRT and achieved CR. The second patient relapsed after 15 months, received palliative paraspinal XRT, refused further chemotherapy, remained alive for 6.5 years and died due to progressive disease unresponsive to chemotherapy. One patient with PD after HDC ASCT achieved CR after 3060 cGy mediastinal and neck XRT. One patient who had localized relapse after HDC ASCT also achieved CR after 4140 cGy mediastinal and right axillary XRT. Three of these patients are in continuous CR.
Of the 43 patients (45% of total) with PR/NR/SD after salvage chemotherapy, 26 achieved CR after HDC ASCT (15 patients (26%) were already in CR after ESHAP). Combining all the CR/CRu/continuous CR and the 3 CR from XRT post-HDC ASCT, total of 44 (76%) patients achieved CR. Median follow-up from diagnosis is 63 months and from ASCT 43 months. Only 3 alive patients Table 2 Prognostic features at diagnosis and at relapse and their impact on event-free survival and overall survival Table 2 shows the impact of various prognostic factors. Presence or absence of all these factors were reviewed at the time of relapse/progression (before the initiation of salvage chemotherapy). Only five patients for LDH and one patient for HL IPI have missing values before salvage chemotherapy. Their impact on EFS and OS using univariate and multivariate analysis are shown in Table 2 . Using KaplanMeier method, probability of EFS is 45% at 136 months ( Figure 1 ). Median EFS is 29.5 months. Probability of OS is 55% at 136 months, median has not reached yet (Figure 1 ). Probability of OS for patients with B symptoms is 27% with median OS of 25.6 months at 127 months follow-up. In patients with no B symptoms (which is 60%) median has not reached yet, P ¼ 0.0025 (log-rank method) for B symptoms vs no B symptoms ( Figure 2) .
As response to salvage is one of the most important factors for long-term outcome, this was separately analyzed as an additional factor as two groups: CR/CRu vs PR/NR/ SD and CR/CRu/PR vs NR/SD. These two groups were analyzed separately among the entire variables mentioned in multivariate analysis for OS and EFS (Table 2) . We have not included this in the main table as all the factors in Table 2 are preexisting factors before the initiation of salvage chemotherapy and patients with progression on chemotherapy were not eligible for transplant like any other study.
For OS, when CR/CRu/PR vs NR/SD was included in this analysis, all the results remained unchanged for significance in multivariate analysis and B symptoms remained the only significant factor, P value changed from 0.032 to 0.037. When CR/CRu vs PR/NR/SD was included, results for all the factors in Table 2 for OS remained unchanged for significance and P value of B symptoms at relapse for OS changed from 0.032 to 0.083 and CR/CRu P value became the only significant factor at 0.004. All 15 patients who had CR/CRu before HDC ASCT were alive as compared to only 49% with no CR/ CRu, Pp0.0001 (Fisher's exact test).
For EFS and inclusion of CR/CRu/PR vs NR/SD in this analysis, all the results remained unchanged for significance. When CR/CRu vs PR/NR/SD was included, patients with CR/CRu after salvage chemotherapy had EFS of 93% compare to 30% in patients with no CR/CRu to salvage chemotherapy Pp0.0001 (Fisher's exact test). On multivariate for EFS, CR/CRu was the only significant factor, P ¼ 0.003 among other factors. The only patient who died in CR in this group was a young boy who died of drowning.
Discussion
To our knowledge, this is the first report comprehensively addressing prognostic factors in adolescent patients who received HDC ASCT in a uniform manner, and the outcome data are encouraging, given the type of patients transplanted. The only factor with negative impact on OS was presence of B symptoms at the time of relapse or progression. We also evaluated response to salvage chemotherapy separately and identified CR/CRu as an important indicator for better EFS and OS.
Other investigators have also reported B symptoms 10, 11, 16 and response to salvage 10, 12, 15, 16, 18, 20 as being important prognostic factors. Whether these patients truly benefited significantly from HDC ASCT or having a response and CR would be enough to continue same salvage chemotherapy with out HDC ASCT is difficult to answer as these and other studies are nonrandomized studies. Patients with less than CR from salvage chemotherapy are reported to have poor outcome in these studies. These patients are potential candidates for investigational therapies like other salvage chemotherapy and newer combinations.
For European Group for Blood and Marrow Transplant, Williams et al. 21 reported 81 pediatrics patients (age range 3.1-16 years) and compared with case matched adult Transplant in adolescent patients with HL S Akhtar et al patients who had BMT. At a median follow-up of 36 months, PFS was 39% for pediatrics and 48% for adults (P ¼ 0.64), 32% of these patients had resistant disease. Baker et al. 22 reported 53 pediatrics/adolescent patients with 6 patients less than 13 years and rest aged 13-21 years. These patients had relatively uniform management; 21% of them were resistant cases. They compared this group with 282 patients 421 years. PFS and OS at 5 years were same; 31 and 43% in pediatrics/adolescent and 29 and 42% in patients 421 years, respectively. Elevated LDH was a bad prognostic factor for both PFS and OS. Leiskovsky et al. 25 reported 41 pediatric patients aged 7-20 years and reported EFS of 53% and OS of 68% at 5 years of median F/U. Only 12% patients had resistant disease. Extranodal disease at first relapse, mediastinal mass at the time of ASCT and primary induction failure were predictors of poor OS and EFS. Verdeguer et al. 23 reported 20 pediatric patients (age range 5-18 years) with a median follow-up of 40 months. Only 10% of the patients had RP-HL. Most patients were in CR (80%) before ASCT. They reported EFS of 62% and OS of 95%.
The outcome of HDC ASCT in PR-HL is not as encouraging as in relapsed HL. Most studies have reported the results of relapsed and refractory HL combined. This has resulted in less than optimal outcome for relapsed and more than expected for PR-HL patients. Studies reporting these two clinical situations separately are limited. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] There is no common definition for PR-HL. Some studies selected patients the way we did 14, 17, 19, 25, 30 but some used even more strict criteria, 9, 11, 12, 13, 31 that is, patients with disease progression while on chemotherapy or progression within 3 months after PR. Comparison of adult patients with PR-HL who had HDC ASCT with other treatment modality, such as salvage chemotherapy or radical XRT, is limited to few randomized trials 3, 4 and mainly nonrandomized reports. 12, 14, 17, 20, 32 These reports have varying results from as good as HDC ASCT (for EFS) to worse than HDC ASCT. No such trial is available in the pediatric/adolescent population. Most studies reported adolescent patients (age range 12-21) with adults and separate analysis is not provided. It is also difficult to compare salvage chemotherapy alone vs HDC ASCT as most patients who have chemosensitive disease to salvage chemotherapy usually proceed to HDC ASCT and those who are progressing are not usually offered HDC ASCT. 14 Josting et al.
14 reported large percentage of the patients on salvage had progressive disease on salvage (60%), severe toxicity (11%) and were excluded from HDC ASCT program. Morabito et al. 20 also reported that 29% patients were not candidates for curative intent therapy. In their analysis, HDC ASCT clearly showed survival benefit over conventional dose salvage chemotherapy, 4-year OS 81 vs 38%. Some other studies had also reported superior EFS favoring HDC ASCT over salvage chemotherapy alone. 12, 17, 32 In conclusion, in adolescent patients with relapsed or PR-HL, ESHAP þ BEAM combination±XRT resulted in 83% response rate and 71% CR rate. Despite this high responsiveness, 32% of patients with CR had relapsed. Twenty-two (38%) patients had died after HDC ASCT mainly due to disease except one patient in CR who died of drowning. At a median follow-up of 43 months from HDC ASCT, probability of EFS is only 45% and OS is 55%. B symptoms at relapse/progression had a negative impact on outcome. Patients with CR/CRu after salvage chemotherapy had a superior outcome. Despite these results, HDC ASCT is considered standard option for this group. Better treatment strategies and understanding of prognostic factor may improve selecting patients for more aggressive therapies.
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